Herceptin: HERalding a new era in breast cancer care but at what cost?

Scalability! But at what COST?

We offer a new metric for big data platforms, COST, or the Configuration that Outperforms a Single Thread. The COST of a given platform for a given problem is the hardware configuration required before the platform outperforms a competent single-threaded implementation. COST weighs a system’s scalability against the overheads introduced by the system, and indicates the actual performance gains ...

Small Interfering RNAs: Heralding a New Era in Gene Therapy

Last decades have witnessed a tremendous expansion in knowledge and availability of the genome sequence, which was of great importance for advancements in the field of gene therapy. This led to improved strategies based on use of nucleic acids with sequences complementary to specific target genes in treatment of many diseases. Especially, advancements have been achieved in discovery and use of ...

PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era

PURPOSE OF REVIEW The first monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) have been approved for clinical use. This timely review highlights recent developments. RECENT FINDINGS Low-density lipoprotein cholesterol (LDL-C) is the primary driver of atherosclerosis and the key target for intervention. Yet despite best treatment including statins, attaining...

Amitriptyline: still efficacious, but at what cost?

Distributed Machine Learning - but at what COST?

Training machine learning models at scale is a popular workload for distributed data flow systems. However, as these systems were originally built to fulfill quite different requirements it remains an open question how effectively they actually perform for ML workloads. In this paper we argue that benchmarking of large scale ML systems should consider state of the art, single machine libraries ...